Our observation that the survival probability of ERBB2 positive patients (when their surviving time is longer than 2 years) was longer than that of ERBB2 negative patients in our GCA cohort, probably also reflects the similarity between esophageal adenocarcinoma features and GCA. The gene discussed is ERBB2; the disease is esophageal adenocarcinoma.